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Etk/Bmx, a member of the Tec family of nonreceptor
protein-tyrosine kinases, is characterized by an N-ter-
minal pleckstrin homology domain and has been shown
to be a downstream effector of phosphatidylinositol 3-ki-
nase. P21-activated kinase 1 (Pak1), another well char-
acterized effector of phosphatidylinositol 3-kinase, has
been implicated in the progression of breast cancer
cells. In this study, we characterized the role of Etk in
mammary development and tumorigenesis and explored
the functional interactions between Etk and Pak1. We
report that Etk expression is developmentally regulated
in the mammary gland. Using transient transfection,
coimmunoprecipitation and glutathione S-transferase-
pull down assays, we showed that Etk directly associ-
ates with Pak1 via its N-terminal pleckstrin homology
domain and also phosphorylates Pak1 on tyrosine resi-
dues. The expression of wild-type Etk in a non-invasive
human breast cancer MCF-7 cells significantly in-
creased proliferation and anchorage-independent
growth of epithelial cancer cells. Conversely, expression
of kinase-inactive mutant Etk-KQ suppressed the prolif-
eration, anchorage-independent growth, and tumorige-
nicity of human breast cancer MDA-MB435 cells. These
results indicate that Pak1 is a target of Etk and that Etk
controls the proliferation as well as the anchorage-inde-
pendent and tumorigenic growth of mammary epithelial
cancer cells.
Epithelial and endothelial tyrosine kinase (Etk, also called
Bmx)1 belongs to the Tec family of nonreceptor protein-tyrosine
kinases that are characterized by an N-terminal Tec homology
domain located downstream of a pleckstrin homology (PH)
domain (1–3). In addition, Etk contains Src homology-3 (SH3)
and -2 (SH2) domains, and a catalytic kinase domain (4). The
PH domain protein module is commonly found in signal trans-
duction proteins and is believed to help mediate lipid-protein or
protein-protein interactions (5). The PH domains of Etk and
Btk (a related Tec family member) have been shown to interact
with heterotrimeric G protein and protein kinase C (6, 7), and
these interactions are believed to regulate kinase activity. Re-
cent studies suggest that activation of PI3-kinase stimulate
Etk, probably because of the direct interaction between the
lipid product resulting from PI3-kinase reaction and the PH
domain of Etk (8). The PH domain is believed to be important
because germline mutation in the PH domain of Btk leads to
human X-linked agammaglobulinemia (1, 2, 9). In contrast,
overexpression of kinase-active Btk induces cellular transfor-
mation and protects cells from apoptotic signals (10). Although
most of the Tec family kinases such as Btk, Itk, and Tec are of
hematopoietic origin, Etk is found to be expressed in a variety
of tissues and cell types, including lung and prostate tissues
and salivary epithelial and endothelial cells (3, 4, 11).
Because Etk is a cytoplasmic kinase with several motifs
characteristic of signaling molecules, it has been implicated in
signal transduction networks. For example, Etk/Bmx was
shown to mediate activation of Rho and serum response factor
in response to the heterotrimeric G proteins Ga-12 and -13 that
can be activated by hormones and neurotransmitters (6). In
addition, Etk was shown to be a substrate of Src kinases and to
be responsible for Src activation of signal transducer and acti-
vator of transcription factor 3 (STAT3) and for cellular trans-
formation (12). Experiments using a kinase inactive mutant
Etk-KQ showed that Etk kinase activity was required for in-
terleukin 6-induced neuroendocrine differentiation of prostate
cancer cells (4). Furthermore, dominant-negative mutants of
PI3-kinase blocked interleukin 6-induced stimulation of Etk in
this system, suggesting that Etk is an effector of PI3-kinase (4).
In addition to Etk, the p21-activated kinases (Paks) repre-
sent another well characterized family of effectors of PI3-ki-
nase. Pak1 is a direct target of the small GTPases Cdc42 and
Rac1, and binding of GTPases to Pak1 stimulates its kinase
activity via autophosphorylation (13). Expression of kinase-
active Pak1 mutant triggers the formation of lamellipodia,
dissolution of stress fibers, and dissolution of focal adhesion
complexes in fibroblast cells (14, 15). Expression of another
kinase-active Pak1 mutant with a mutation in GTPase binding
sites triggers the formation of actin ruffles (15–17). Pak1 ki-
nase activity is essential for the formation of polarized lamel-
lipodia at the leading edge (18) and for actin-myosin-mediated
cytoskeletal changes (19). Expression of the kinase-inactive
Pak1 mutant blocks the ability of Ras to induce transformation
of Rat1 fibroblast (20), suggesting that Pak1 plays a role in this
cell transformation. Furthermore, expression of kinase-active
Pak1 in breast cancer cells stimulates anchorage-independent
growth (21, 22).
Despite the recent reports of the involvement of Etk in sig-
naling cascades in human cancer cells and the fact both Etk
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and Pak1 are downstream of PI3-kinase, the relationship be-
tween Etk and Pak1 kinase and the role of the Etk pathway in
the biology of human mammary epithelial cancer cells remain
unknown. We sought to determine the role of Etk pathway in
breast cancer cells. We present new evidence that Etk is an
upstream effector of Pak1 tyrosine phosphorylation and that it
is directly associates with Pak1. Furthermore, we found that
Etk activity is discovered to be required for the proliferation,
anchorage-independent growth, and tumorigenicity of mam-
mary epithelial cancer cells. These results indicate that Pak1 is
a target of Etk and that Etk regulates the anchorage-indepen-
dent and tumorigenic growth of mammary epithelial cancer
cells.
EXPERIMENTAL PROCEDURES
Plasmids and Antibodies—T7-tagged wild-type (Wt) pcDNA3-T7-Etk
(T7-Etk), kinase-inactive pcDNA-T7-Etk (Etk-KQ), and N-terminal and
C-terminal deletion mutants of Etk were previously described (4, 12).
N-Ter ETK contains amino acids 1–240 and C-Ter has amino acid
243–674 (4, 12). Myc-tagged Pak1 Wt and Pak1 K299R mutants were
generously provided by Jonathan Chernoff and have been earlier de-
scribed (16, 18). To construct T7-tagged central inhibitory fragment of
Pak1 (Pak aa 83–149, Ref. 18) Pak1 aa 83–149 domain was amplified by
PCR and subcloned into pcDNA3.1 His (Invitrogen). Antibodies di-
rected against T7, phosphotyrosine, Pak1, and c-Myc were purchased
from Novagen, Upstate Biotechnology, Santa Cruz Biotechnology, and
Neomarkers, respectively. Dr Hsing-Jien Kung kindly provided mono-
clonal antibody to Etk.
Cell Culture and Transfection—MCF-7, MDA-MB435 human breast
cancer cell lines (18), were maintained in Dulbecco’s modified Eagle’s
medium (DMEM)/F12 (1:1) supplemented with 10% fetal bovine serum.
Cells were transfected with the desired vector using Fugene-6 reagent
(Roche, Nutley). Clonal stable cell lines overexpressing Wt-Etk or
Etk-KQ or control pcDNA were selected in the presence of G418 resist-
ance (500 mg/ml).
Immunoprecipitation and Kinase Assay—Cells were lysed in a buffer
containing 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10% glycerol, 1%
Nonidet P-40, 10 mM NaF, 1 mM NaVO4, and a mixture of protease
inhibitors. The T7-tagged Etk or Myc-tagged Pak1 were immunopre-
cipitated from the cell lysates with mAbs directly against T7 or Myc,
respectively, as described (23). When indicated, the immuncomplex was
washed with kinase buffer (20 mM HEPES, pH 7.4, 1 mM dithiothreitol,
10 mM MnCl2, and 10 mM MgCl2). The kinase reaction was carried out
in buffer supplemented with 7.5 mg of enolase (Sigma) for the Etk
kinase assay and with myelin basic protein (MBP) for the Pak kinase
assay.
GST Pull-down Assay—Wt-Etk, N-Ter, and C-terminal Etk cDNA (4,
12) were translated in vitro using the TNT reaction kit (Promega) in the
presence of [35S]methionine. Subsequently, 10 ml of reaction volume
was diluted in 400 ml of protein-binding buffer (20 mM Tris, pH 7.5, 50
mM NaCl, 10% glycerol, 10 mM NaF, 1% Nonidet P-40, 1 mM NaV04, and
protease inhibitors) and incubated with 2 mg of Pak1-GST or GST
protein beads at 4 °C for 4 h. The beads were washed six times with 1
ml of each binding buffer and eluted with 23 SDS-polyacrylamide gel
electrophoresis sample buffer. Elutes were resolved onto a 10% SDS-
polyacrylamide gel electrophoresis and visualized using a
phosphorimager.
Cell Proliferation and Soft Agar Colony Formation Assays—MCF-7
and MDA-MB435 cells (2 3 104 cells per well in a 24-well plate) and
counted daily for six days. Anchorage-independent colony assays were
performed as described previously (21, 23). Briefly 1 ml of solution of
0.6% DIFCO Agar in DMEM supplemented with 10% fetal bovine
serum was layered onto 60 3 15 mm tissue culture plates. MCF-7 or
MDA-MB 435 cells (10,000 cells) were mixed with 1 ml of 0.36% Bac-
toagar solution in DMEM prepared in a similar manner and layered on
top of the 0.6% Bactoagar layer. Plates were incubated at 37 °C in 5%
CO2 for two weeks. In dominant negative Pak1 experiment, MCF-7 cells
or Wt-ETK cells were transfected with 10 mg of GFP or GFP-K299R
Pak1 or GFP-Pak1 inhibitor and tested for anchorage-independent
growth.
Tumorigenecity Studies—Exponentially growing cells (3 3 106) were
injected into mammary fat pad (two sites/animal) of female athymic
mice (Nu/Nu, 4 weeks old). Every fourth day, tumor volumes were
measured with calipers along two major axes. Tumor volume was cal-
culated as follows V 5 (4/3)p R12 R2, where R1 is radius 1 and R2 is
radius 2 and R1 , R2 (n 5 10 per group) (24).
Apoptosis—Tunnel method was used to detect DNA fragmentation as
previously described by Gabriel et al. (25). Briefly, paraffin-embedded
sections pretreated with protease were nicked and labeled with bioti-
nylated poly(dU), introduced by terminal deoxy-transferase, and then
stained using avidin-conjugated peroxidase.
Reverse Transcription (RT)-PCR and Southern Hybridization—Total
cytoplasmic RNA was isolated from different stages of mice tissue using
the Trizol Reagent (Life Technologies, Inc.) and 500 ng of RNA analyzed
by RT-PCR. The forward primer for mEtk was 59-CACACCACCTCAAA-
GATTTCATGG-39 and the reverse primer was 59-CATACTGCCCCTTC-
CACTTGC-39. RT-PCR products were run onto 1% agarose gel, trans-
ferred to a blot, and probed with a 520-bp cDNA of mEtk.
In Situ Hybridization—For in situ hybridization, mouse mammary
glands or 12-day-old embryos were dissected out and fixed with 4%
paraformaldehyde. The tissues were processed into 10 mm of frozen
sections, and in situ hybridization was performed as described (24). To
make the probe, the Etk cDNA fragment was cloned to TOPO II vector,
and RNA probe was labeled with digoxigenin and was synthesized by in
vitro transcription. Sense-probe hybridization was used as background
control.
RESULTS
Etk Expression during Embryogenesis and Mammary Gland
Development—To explore the role of Etk during cell prolifera-
tion and differentiation, we first explored the expression profile
of Etk during mouse embryonic development using in situ
hybridization. As shown in Fig. 1, Etk mRNA was expressed in
most tissues, with highest levels in the nervous and epithelial
tissues, i.e. encephalon, dorsal root ganglia, pancreas, lung,
and the intestinal mucosa. Etk mRNA signals in the vertebral
column and hearts were significantly lower. In situ hybridiza-
tion analysis of mouse mammary gland demonstrated that Etk
mRNA signal was much stronger in the lactating alveoli than
in the pregnant mammary gland (Fig. 2A).
Etk/Bmx is usually the only Tec family kinase expressed in
FIG. 1. Etk expression during embryogenesis. In situ hybridiza-
tion using antisense (AS) or sense (S) probe. High Etk expression in
high levels in the nervous and epithelial tissue, i.e. the dorsal root
ganglia (Drg), the mucosa of the intestine (Int), the pancreas (Pan), and
the lung (Lu).
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epithelial cells, but the expression level is generally low. De-
spite the low level, accumulating evidence suggests that it play
an important role in the growth, differentiation, and apoptosis
of epithelial cell (26). To understand the potential function of
Etk in mammary gland, we investigated Etk expression during
various stages of the mammary gland development by RT-PCR
followed by Southern hybridization with a fragment of human
Etk cDNA. Results indicated that Etk expression appears to
undergo a cyclic change as the expression levels of Etk were
down-regulated during pregnancy, early lactation, and again
during the late stages of lactation (Fig. 2, B and C). Etk ex-
pression was lowest during pregnancy, a stage of high prolif-
eration for mammary glands (Fig. 2, B and C), and highest in
non-proliferative weaning and virgin mammary glands, sug-
gesting that Etk may have an important role in the biology of
mammary epithelial cells.
Expression and Activation of Etk in Breast Cancer Cells—
Because the potential role of Etk in mammary epithelial cancer
cells is not known, we next examined the expression of Etk in
a panel of breast cancer cell lines by Southern hybridization.
Among the breast cancer cell lines used, highly tumorigenic
and metastatic MDA-MB435 cells exhibited the highest Etk
content, whereas the Etk content of MCF-7 and SKBR-3 was
lower (Fig. 2D). Because MCF-7 and SKBR-3 cells do not form
tumors and metastasis in vivo, it appears that Etk expression
may correlate with the degree of transformation of breast can-
cer cell lines used here.
To assess the physiological significance of Etk expression in
breast cancer cells, we sought to determine whether Etk kinase
activity can be stimulated by physiologically relevant mole-
cules in mammary gland, as heregulin-b 1 (HRG), a polypep-
tide growth factor with a role in the development and tumori-
genesis of mammary epithelial cells (18). Indeed, we found that
HRG activated the autophosphorylation of Etk in MCF-7
breast cancer cells (Fig. 3A). Because of the low level of expres-
sion and relatively low avidity of the antibodies currently avail-
able, it has been difficult to visualize endogenous Etk in cell
biology study. Therefore, we resorted to express T7-tagged Etk
for this type of analysis.
Pak1 Phosphorylation and Activation by Etk in Breast Can-
FIG. 2. Etk expression during the mammary gland develop-
ment. A, in situ hybridization, a strong Etk signal was observed in the
epithelial cells during lactation (L, day 4) but not pregnancy (P, day 15)
stage. L/S, sense probe hybridization in the lactation mammary gland.
B, RNA (1 mg) at various stages of mammary gland development (V,
virgin weeks; L, lactation days) was analyzed for the expression of Etk
and GAPDH control by RT-PCR followed by Southern hybridization. C,
RNA at virgin (V), pregnancy (P), lactation (L) and post weaning (PW)
stages (days) of mammary gland development was analyzed. D, expres-
sion of Etk in breast cancer cells. RNA (1 mg) from the indicated cell
lines was analyzed for Etk expression by RT-PCR followed by Southern
hybridization. The results are representative of two similar
experiments.
FIG. 3. Etk regulation of Pak1 in MCF-7 breast cancer cells. A,
HRG stimulation of Etk kinase activity. T7-tagged Etk was transfected
into cells (lanes 2 and 3), and cells were treated with HRG (30 ng/ml) for
10 min (lane 3). Immunoprecipitated (IP) Etk was used for an in vitro
kinase, and the phosphorylated Etk is shown (upper panel). Immuno-
precipitated Etk was immunoblotted with anti-T7 antibody (lower pan-
el). B, Etk stimulates tyrosine phosphorylation and kinase activity of
Pak1. Cells were transfected with Myc-Pak1 with or without T7-Etk.
Cell lysates were immunoprecipitated with Myc antibody and subjected
to in vitro kinase assay using MBP. The reaction products were resolved
by 10% SDS-polyacrylamide gel electrophoresis and transferred to a
nitrocellulose and autoradiograph showing MBP phosphorylation (first
panel). The blot was reprobed with mAb 4G10 to show Pak1 tyrosine
phosphorylation (second panel) and then with Myc antibody (fourth
panel). Cell lysates were immunoprecipitated with T7-antibody to show
the expression of T7-Etk (third panel). C, cells were co-transfected with
Myc-Pak1 and T7-Etk in the presence or absence of DN-Pak1. Cell
lysates were immunoprecipitated with Myc antibody and subjected to in
vitro kinase assay using MBP, and the blot was blotted with Myc
antibody. D, Etk interacts with Pak1 in vivo. Cells were transfected
with Myc-Pak1 or T7-Etk or both. Cell lysates were immunoprecipi-
tated with antibodies directed against T7 or Myc and Western blotted
with antibodies against T7 or Myc as indicated. E, stable clones ex-
pressing Pak1 inhibitors and pcDNA control cells were transfected with
Wt-Etk, immunoprecipitated with Pak1, and subjected to in vitro ki-
nase assay using MBP (upper panel). Cell lysates were immunoprecipi-
tated with T7 antibody to show the expression of T7-Etk (middle panel).
The expression of Pak1 inhibitors were verified by PCR (lower panel). F,
GST pull-down assays to show the association of Pak1 with the in vitro
translated Wt-Etk, N-Ter-Etk, or C-Ter-Etk. The first three lanes show
the inputs. The results are representative of three similar experiments.
Etk/Bmx Tyrosine Kinase Activates Pak1 29405
 by guest on M
arch 14, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
cer Cells—Because both Etk and Pak1 are downstream of
PI3-kinase, we sought to determine whether Etk could acti-
vate Pak1. Co-transfection of MCF-7 cells with T7-tagged Etk
and Myc-tagged Pak1 constructs significantly increased Pak1
kinase activity as determined by an immune-complex kinase
assay using MBP as a substrate (Fig. 3B, upper panel). Be-
cause Etk is a tyrosine kinase, we hypothesized that Etk
phosphorylates Pak1 on tyrosine residues. Indeed, we discov-
ered that co-transfection of Etk and Pak1 was accompanied
by a substantial stimulation of tyrosine phosphorylation of
Pak1 (Fig. 3B, lower panel). To verify that Pak1 is down-
stream of Etk, we next demonstrated that coexpression of a
kinase-defective K299R Pak1 mutant protein (designated
dominant-negative (DN)-Pak1) suppressed the ability of Etk
to activate Pak1 kinase activity (Fig. 3C). In the targeted
Pak1 K299R sequence, the lysine 299 ATP binding site was
replaced by arginine, rendering Pak1 catalytically defective
as shown by us and others in cell lines (16, 18). To rule out
that the observed inhibitory effect of Pak1 K299R mutant
was not due to ineffective transduction of Cdc42/Rac signals,
we next generated stable MCF-7 clones expressing the cen-
tral inhibitory fragment of Pak1 aa 83–149 (Fig. 3D, upper
panel), which does not interfere with cdc42/Rac1 binding.
These stable cell lines expressing control vector or the central
Pak inhibitor were transfected with T7-tagged Etk, and the
effect Etk on Pak1 kinase activity was measured by subject-
ing the immunoprecipitated T7-Etk to in vitro kinase assay
using MBP as a substrate. The Etk was able to activate Pak1
activity in vector-transfected cells but not in the cells that
express Pak inhibitor aa 83–149 (Fig. 3D). Together, these
results confirm that Etk regulates Pak kinase activity. While
at present, we do not know whether tyrosine phosphorylation
of Pak1 induced by Etk contributes to its elevated activity. To
our knowledge, this is the first report that shows that Pak1 is
tyrosine-phosphorylated and serves as a downstream sub-
strate of Tec family of kinase. While interesting and repro-
ducible, at present we do not know the significance of the
tyrosine phosphorylation, and experiments are planned to
explore the significance of this finding.
Interaction of Etk with Pak1 in Vivo—To determine whether
the observed activation of Pak1 by Etk is due to interactions
between the two proteins, we examined the association be-
tween T7-tagged Etk and Myc-tagged Pak1 in vivo by recipro-
cal co-immunoprecipitation and Western blot assays. Results of
a representative experiment are shown in Fig. 3E. Transient
expression of T7-tagged Etk, but not of control T7 vector, in
MCF-7 cells was accompanied by the association of T7-tagged
Etk with Myc-tagged Pak1 in both immunoprecipitation exper-
iments. These results suggest that Etk associates with Pak1
and stimulates tyrosine phosphorylation and kinase activity of
Pak1 (Fig. 3E).
To determine whether the observed association between Etk
and Pak1 was direct or mediated via other proteins, we exam-
ined the ability of in vitro translated Wt-Etk or Etk-KQ protein
to bind GST-Pak1 in GST pull-down assays. As shown in Fig.
3F, Etk and its N-terminal domain (aa 1–240) strongly interact
with GST-Pak1; very little interaction was seen between Etk
C-terminal domain (aa 243–674) and GST-Pak1, and GST
alone provided a proper negative control.
Etk in Proliferation and Anchorage-independent Growth of
Breast Cancer Cells—To further delineate the contribution of
Etk in the biology of breast cancer cells, we established stable
MCF-7 clones expressing T7-tagged Wt-Elk or kinase-inactive
Etk-KQ or control vector. The results shown in Fig. 4A demon-
strate the expression of tagged Etk in several representative
clones. The functionality of Etk was assessed by performing in
vitro kinase assays using enolase as an exogenous substrate
(Fig. 4B). To determine how Etk affects the Pak1 pathway,
MCF-7/Etk cells were transfected with Myc-Pak1. Overexpres-
sion of Etk in MCF-7 cells was associated with significant
increases in the phosphorylation of Pak1 on tyrosine (Fig. 4C).
MCF-7 cells expressing Wt-Etk were transfected with or with-
out Myc-tagged Pak1, and tagged Pak1 was immunoprecipi-
tated by an anti-Myc mAb and subjected to in vitro kinase
assay. The upper and lower bands in Fig. 4D represent the
autophosphorylated T7-Etk (73 kDa) and Myc-Pak1 (64 kDa),
respectively. These protein bands were identified due to their
differential electrophoretic mobilities in the gel.
To examine the influence of Etk expression on the growth
characteristics of breast epithelial cancer cells, we measured
the proliferation rate and the ability of cells to grow in an
anchorage-independent manner. Compared with vector-trans-
fected control cells, cells in which Wt-Etk was overexpressed
demonstrated greater ability to form larger colonies in soft
agar, and expression of Etk-KQ mutant led to a reduction in
the anchorage-independent growth (Fig. 5,A and B). In addi-
tion, as shown in Fig. 5C, the growth rate of cells expressing
Wt-Etk and Etk-KQ was affected 35–40% more than that of the
control vector-transfected clone. Because Pak1 has been shown
to promote the anchorage-independent growth (21, 22), we next
determined whether dominant-negative Pak1 could modulate
the ability of Wt-Etk cells to form colonies in soft agar. Wt-Etk
cells were transfected with GFP-dominant-negative Pak1 and
GFP-Pak1 inhibitor and used for soft agar assay. As shown in
Fig. 6, A and B, Wt-Etk cells transfected with dominant-nega-
tive Pak1 or Pak1 inhibitor form small colonies compared with
Wt-Etk control cells. Together, these findings suggested that
Pak1 is a downstream effector of Etk pathway and may con-
tribute to the observed phenotypic changes by Etk.
FIG. 4. Overexpression of Etk stimulated Pak1 tyrosine phos-
phorylation. A, characterization of MCF-7 clones expressing T7-
tagged Wt or kinase-inactive (KQ) Etk by Western blotting by anti-T7
mAb or control vinculin Ab. B, baseline Etk kinase activity in Wt-Etk
clones. Lysates of cells were immunoprecipitated with anti-Etk anti-
body, followed by in vitro kinase assays. The autophosphorylated Etk
and enolase as an exogenous substrate of Etk are shown. C, the indi-
cated Wt-Etk clones were transfected with or without Myc-tagged Pak1.
The Myc-Pak1 was immunoprecipitated by an anti-Myc mAb, immuno-
blotted with antiphosphotyrosine Ab, and then immunoblotted with
anti-T7 and Myc mAb. D, Wt clones were transfected with or without
MYC-tagged Pak1, and tagged Pak1 was immunoprecipitated by an
anti-Myc mAb subjected to in vitro kinase assay. Autophosphorylated
Etk and Pak1 are also shown. Results shown are representative of three
experiments.
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Effect of Overexpression of Kinase-inactive Etk of Breast Can-
cer Cells—We next sought to determine whether Etk activity is
required for the maintenance of the transformed phenotypes in
breast cancer cell lines. Highly tumorigenic and invasive MDA-
MB435 cells were stably transfected with T7-tagged kinase-
inactive Etk mutant (Etk-KQ) or with control pcDNA vector
(Fig. 7A, upper panel). As expected from the results shown in
Fig. 4, overexpression of Etk-KQ led to a significant reduction
in Etk and Pak1 kinase activities (Fig. 7B). The expression of
Etk-KQ was accompanied by a significant inhibition of the
growth rate of MDA-MB435 cell (Fig. 7C). In addition, overex-
pression of kinase-inactive Etk-KQ reduced the ability of cells
to grow in soft agar as compared with vector-transfected con-
trol cells (Fig. 7, D and E).
To investigate the significance of Etk expression in vivo, we
next examined the ability of MDA-MB435 clones expressing
kinase-inactive Etk-KQ or vector control in a xenograft model.
In these experiments, cells were implanted into the mammary
fat pad of athymic mice. Inactivation of Etk in MDA-MB435
cells severely affected the ability of cells to form tumors (i.e. by
55–70% compared with vector-transfected cells) (Fig. 8A). His-
tological examinations of tumors with hematoxylin and eosin
staining revealed the presence of necrotic areas in tumors from
Etk-KQ clones (data not shown). Reevaluation of these tumors
with TUNEL staining confirmed that apoptosis was wide-
spread in Etk-KQ tumors (Fig. 8B). Together, these findings
suggest that Etk expression may be required for the mainte-
nance of transformed phenotypes in breast cancer cells.
FIG. 5. Etk regulation of cell growth and anchorage-indepen-
dent growth of breast cancer cells. The effects of Wt-Etk and
Etk-KQ expression on anchorage-independent growth of MCF-7 cells.
MCF-7 cells, Wt-Etk and Etk-KQ cells (104 cells/plate) were seeded in
soft agar dishes (35-mm diameter) and colonies with diameters larger
than 1 mm were counted after 2 weeks of incubation. The results are
representative of three similar experiments. B, the numbers given are
mean values 6 S.E. of three independent experiments performed in
triplicate. C, the effects of Wt-Etk or Etk-KQ expression on the growth
rate of MCF-7 cells. Cells were seeded at a density of 2 3 104 in 24-well
tissue culture plates in 10% fetal bovine serum/DMEM. After 4 and 6
days, cells were counted using a coulter counter. Each point represents
the mean 6 S.E. of two replicate wells. Asterisks indicate p , 0.05 by
Student’s t tests.
FIG. 6. Dominant-negative inhibition of Pak1 reduces soft
agar cloning efficiency of Wt-Etk cells. A, MCF-7 cells and Wt-Etk
cells were transfected with GFP-K299R Pak1 or GFP-Pak1 inhibitor
and tested for anchorage-independent growth. Using a fluorescent lamp
with excitation for GFP visualization captured the images presented on
the left panel, and the right panel represents the phase contrast image
of the same microscopic field to show total cells. B, the colony diameters
of Wt-Etk cells transfected with Pak1 K299R and Pak1 inhibitor aa
83–149. Representation results from two independent experiments are
shown here.
FIG. 7. Kinase-defective Etk inhibits tumorigenicity of breast
cancer cells. A, characterization of MDA-MB435 clones expressing
T7-Etk by Western blotting with anti-T7 mAb and with vinculin Ab. B,
Etk and Pak1 kinase activities in Etk-KQ cells. Etk-KQ cells were
immunoprecipitated with anti-Etk antibody or PAK1 antibody followed
by in vitro kinase assays. The autophosphorylates Etk (upper panel)
and enolase (substrate for Etk) or MBP (substrate for Pak1) (lower
panel) are shown. C, effect of Etk-KQ on the growth rate of exponen-
tially growing clones as determined by counting the numbers of cells. D,
effect of Etk-KQ expression on anchorage-independent growth of MDA-
MB435 cells over 14 days. E, representative results from two independ-
ent experiments are shown here.
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DISCUSSION
Etk is a member of the Tec family of the nonreceptor
tyrosine kinases that are characterized by N-terminal PH
domains. The PH domain is important in protein-protein
interactions and is involved often in cytoplasmic signaling
cascades. Etk is one of the few Tec family members, which are
expressed in epithelial cells (10). Here we sought to deter-
mine the role of Etk in regulating breast cancer growth
regulation. We report that: 1) Etk expression is developmen-
tally regulated during mammary gland development; 2) Etk
is expressed in the highly tumorigenic MDA-MB435 cell
lines; 3) Etk is tyrosine-phosphorylated and is activated by
physiologically relevant growth factor in breast cancer cells;
4) Etk phosphorylates Pak1 on tyrosine residues, and kinase-
inactive Pak1 mutant blocked Etk activation of Pak1; 5) Etk
directly interacts with Pak1 via the N-terminal PH domain-
containing region; 6) overexpression of Wt-Etk in noninva-
sive breast cancer line enhanced the ability of the cells to
grow in an anchorage-independent manner; and 7) expres-
sion of kinase-inactive Etk inhibits tumorigenic phenotypes
in a highly tumorigenic breast cancer cell line. Taken to-
gether, these observations suggest that Etk play an impor-
tant role in the regulation of mammary epithelial cancer
cells.
The finding that Pak1 kinase activity is stimulated following
Etk kinase activation is important, as it implies that Etk ki-
nase constitutes an initial signal for Pak1 activation. This
hypothesis is supported by several additional observations: 1)
inhibition of Etk kinase by a kinase-defective mutant was
accompanied by concurrent inhibition of Pak1 activity; 2) ex-
pression of dominant-negative Pak1 mutant blocked the ability
of Etk to activate the Pak1 kinase and did not affect the Etk
kinase; 3) Etk directly interacted with Pak1 via its N-terminal
PH domain; and 4) Etk-mediated stimulation of anchorage-
independent growth was blocked by dominant-negative Pak1.
These results suggest that Pak1 may be downstream of Etk
kinase in breast cancer cells. These findings are inconsistent
with those in a recent report (6) that showed activation of Rho
rather than of Cdc42 or Rac1 (upstream regulators of Pak1) by
Tec family members in mouse 3T3 fibroblast cells. To reconcile
these findings, we suggest that the Tec family may utilize
distinct members of the small GTPase family members in epi-
thelial cancer and fibroblast cells in humans and/or mice.
Another notable finding in this study was that Etk induced
tyrosine phosphorylation of Pak1 and that Etk activity is re-
quired for the proliferation, anchorage-independent growth
and tumorigenicity of breast cancer cells. This finding strongly
suggests that Etk utilize Pak1 tyrosine phosphorylation to
influence transformed phenotypes that are generally believed
to be driven by tyrosine phosphorylation. This hypothesis is
further supported by recent findings by us and by others that
overexpression of kinase-active Pak1 mutant (T423E, predom-
inantly serine phosphorylation) in breast cancer cells selec-
tively enhanced the anchorage-independent growth of breast
cancer cells (21, 22). Currently, we do not know the precise
mechanism by which Etk exerts its profound stimulatory ef-
fects in the transformation functions of cancer cells. It is pos-
sible that in addition to Pak1, there are other unidentified
downstream effectors for Etk pathway that contribute the ob-
served phenotypic changes. Studies are in progress to investi-
gate these and other possibilities.
Our findings clearly established, for the first time, that Etk
kinase directly associates with Pak1 and stimulates Pak1 ty-
rosine phosphorylation and that Etk controls the anchorage-
independent growth rate and tumorigenic behavior of human
mammary epithelial cancer cells. These observations open a
new avenue of investigation closely linking the Tec and Pak
families with breast cancer cell activity.
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